Skip to content
Investing

Dave Investor Profile: ExtraCash, 31% Growth and a Justice Department Lawsuit

Dave is a Los Angeles neobank built on ExtraCash advances. Its latest results, $315m of cash and investments, 12.8m shares, the DOJ lawsuit, credit risks and what to watch next.

Dave co-founder and CEO Jason Wilk speaking on stage at the Money 20/20 conference in Las Vegas in October 2019.
Photo: Dave.com employee / Wikimedia Commons, CC BY-SA 4.0

Dave is a Los Angeles-based US neobank that earns most of its money from ExtraCash, a small cash advance, and is now testing a pay-in-four credit card. Revenue is growing by more than 30% a year and the company is profitable, but a Justice Department lawsuit over its fees is unresolved and its shares have lost about 30% in three weeks.

What Dave Does and Where

In its filings Dave describes itself as a mobile-first financial services platform for Americans underserved by traditional banks. It is based at 1265 South Cochran Avenue in Los Angeles, and its Class A shares trade on Nasdaq as DAVE. It came to the market by merging with a blank-cheque company, VPC Impact Acquisition Holdings III, whose name it once carried.

The core product is ExtraCash. Members took $2.5bn of advances in the third quarter, 23% more than a year earlier, and the average advance reached $225 in September. Dave decides how much to advance with its own underwriting model, CashAI, whose sixth version was fully in use by September.

Around ExtraCash sit the Dave Debit Card, on which members spent $533m in the quarter, a Goals savings feature and Dave Flex, a pay-in-four credit card. Flex is still small: active users grew from single-digit to double-digit thousands during the third quarter, and a wider launch is planned for 2027.

Dave relies on two bank partners, according to its filings, and has been moving the funding of ExtraCash to Coastal Community Bank, where about $159m was outstanding at the end of September. Almost all revenue is service-based: $186.3m of the third quarter's $197.7m, against $11.4m of transaction-based revenue.

Dave: share price, chart and news

Dave CEO Jason Wilk speaking on stage at TechCrunch Disrupt 2024 on 28 October 2024.
Dave CEO Jason Wilk speaking on stage at TechCrunch Disrupt 2024 on 28 October 2024. Photo: TechCrunch (Katelyn Tucker / Slava Blazer Photography) / Wikimedia Commons, CC BY 2.0

The Latest Numbers

MeasureQ3 2026Q3 2025Nine months 2026
Revenue$197.7m$150.8m$526.9m
Adjusted EBITDA$81.5m$58.7m$226.3m
Net income (GAAP)$63.8m$92.0m$128.4m
Adjusted diluted EPS$4.39$4.45$12.12
Provision for credit losses$36.6m$29.9m$92.0m

Dave reported third-quarter results on 4 November. Revenue rose 31% and nine-month revenue 35%, from $390.5m. "Q3 was another strong quarter, with revenue growth accelerating to 31% year-over-year," chief executive Jason Wilk said.

Profit per share went the other way. Adjusted earnings per share slipped 1%, as marketing, staff and stock-based pay costs grew faster than sales and credit provisions rose 22%. Non-GAAP gross margin fell to 70% from 72% in the second quarter. GAAP net income fell 31% because the year-earlier figure included a $33.6m tax benefit; this quarter's included $26.3m of non-cash gains on warrant and earnout liabilities.

New members rose 35% to 1.135 million in the quarter and monthly transacting members 18% to 3.15 million. The share of advances 28 days past due was 2.09%, better than 2.15% a year before.

Dave raised its 2026 guidance again, to revenue of $746m to $750m, adjusted EBITDA of $327m to $330m and adjusted earnings of $17.45 to $17.65 a share.

Cash, Shares and Buybacks

Balance sheet, 30 September 2026

  • $315.1m cash, restricted cash and investments
  • $193.5m convertible notes due 2031, net
  • 12.79m shares: 11.48m Class A outstanding plus 1.31m Class V on 26 October

Cash, restricted cash and investments more than doubled from $123.2m at the end of 2025. In early October Dave repaid its $75m debt facility with Victory Park Management, which was still on the balance sheet at the end of September. The convertible notes, issued in 2026, come with capped call options that the company says offset part of the possible dilution.

Dave has been shrinking its share count. Shares held in treasury rose to 1.28 million, at a cost of $257.0m, from 274,490 at the end of 2025, and it spent about $20m on net settlements of staff share awards and buybacks in the third quarter. It has $88m left under its repurchase authorisation. Shareholders' equity fell to $273.8m from $352.7m over the nine months.

At the 12 November close of $267.37, the 12.79 million shares were worth about $3.4bn. The company also has listed warrants, trading as DAVEW, where 32 warrants buy one Class A share at $368.

The Main Risks

What could go wrong

  • Litigation. The FTC sued Dave in November 2024 in the federal court for the Central District of California, alleging misleading marketing of advance amounts, undisclosed fees and tips charged without consent. The Justice Department took over the case with an amended complaint on 30 December 2024 that names Wilk and seeks civil penalties. It is unresolved. Dave also faces a Military Lending Act class action, whose appeal is due for oral argument on 16 November, and consumer protection suits from the City of Baltimore and a Pennsylvania district attorney.
  • Credit. Provisions for credit losses reached $92.0m in nine months, from $65.7m a year before, and the company has had to recalibrate its loss forecast.
  • Partners and funding. Dave depends on two bank partners and on outside funding for its advances.
  • Dilution. The convertible notes and warrants could add shares if the price rises far enough.
  • Volatility. The shares fell 18.1% on 5 November, the day after the results.

Dave's legal settlement accrual stood at $10.0m at the end of September, up from $7.8m at the end of 2025, and legal settlement and litigation costs were $11.3m in the first nine months.

What to Watch Next

WhenWhat
16 November 2026Ninth Circuit hearing on Dave's appeal in the Military Lending Act class action
Q4 2026Whether the 28-day past-due rate stays below 2%, as management expects
Q4 2026Non-GAAP gross margin back above the second quarter's 72%
Full year 2026Revenue of $746m to $750m and adjusted EBITDA of $327m to $330m
Early 2027Fourth-quarter results; the 2025 annual report was filed on 2 March 2026
2027The planned wider rollout of Dave Flex
No date setThe outcome of the Justice Department lawsuit

The full-year guidance implies fourth-quarter revenue of $219m to $223m, against $197.7m in the third quarter. Credit is the number to watch: management says the fourth quarter is tracking in line with September, when the past-due rate dipped below 2%.

Sources

Related stories

Markets

Dave Shares Sink 18% as Credit Costs Dent Earnings Despite Another Guidance Raise

Dave lifted 2026 revenue guidance to $746m-$750m after sales rose 31%, but higher credit provisions and an adjusted earnings miss sent the neobank's shares down 18.1% on 5…

Investing

D-Wave Quantum: Investor Profile of the Annealing Pioneer Building a Gate-Model Machine

D-Wave Quantum sells quantum computing through the cloud, on-site systems and services. It holds $503m of cash and securities and a growing order book, but its losses keep rising.

Investing

Bitdeer Technologies: Investor Profile of the Bitcoin Miner Turning to AI Cloud

Bitdeer Technologies mines bitcoin with its own SEALMINER machines and is turning power sites into AI data centres. Its sites, latest numbers, $1.95bn of borrowings, main risks and…

Investing

Quantum Computing Inc.: Investor Profile of the Photonics Maker With $1.3bn in the Bank

Quantum Computing Inc. sells photonic chips, packaging services and room-temperature quantum optimisation machines. It has about $1.3bn in cash and investments, but sales are small…

Investing

Aya Gold & Silver Corrects Q3 Cash Costs to $14.28 an Ounce After Silver Double Count

Aya Gold & Silver refiled its Q3 MD&A after silver in transit was deducted twice. Zgounder ounces sold rise to 1,392,478 and cash costs fall to $14.28 from $15.51. Revenue and…

Investing

FDA Rejects Summit's Lung Cancer Drug Ivonescimab Over Phase 3 Survival Miss

The FDA has rejected Summit Therapeutics' lung cancer drug ivonescimab, saying slower tumour growth in the phase 3 HARMONi trial was not enough without a clear gain in survival.

Investing

Red Cat Withdraws Its $150m to $180m 2026 Revenue Target After $11.8m Third Quarter

Red Cat Holdings has withdrawn its $150m to $180m revenue target for 2026 after third-quarter sales of $11.8m, blaming slower defence funding. Its quarterly net loss more than…

Investing

Berkshire Reveals $689m Bending Spoons Stake, Doubles Lennar and Trims Bank of America Again

Berkshire Hathaway's third-quarter 13F shows a new Bending Spoons stake worth $689m, a doubled Lennar holding and 27.5 million more Bank of America shares sold, while Apple stayed…